Melanoma has been one of the most active areas of cancer research for the past 15 years. Immunotherapy and targeted therapy — the treatments that transformed the outlook for advanced disease — both reached patients through clinical trials, and the next generation of treatments is being tested now. For someone with advanced melanoma, a trial is not a last resort; it can be a reasonable option at almost any point.
This page explains what trial phases mean, how eligibility works, where to search, and what to ask before enrolling. For a general introduction to trials across all stages, see melanoma clinical trials. For newer treatments that are often accessed through trials, see TIL therapy and newer options.
There is a common assumption that clinical trials are only for people who have exhausted every standard treatment. That is not how melanoma trials are designed:
•Before and after surgery. Trials are testing new drugs and combinations given before surgery (neoadjuvant) and after it (adjuvant) for stage III melanoma.
•As first treatment for metastatic disease. Some trials compare a promising new combination against the current standard as the very first systemic therapy.
•After other treatments. Many trials enroll people whose melanoma has progressed on checkpoint inhibitors or targeted therapy, testing new mechanisms.
Asking early has a practical advantage: some trials require that you have not already received certain treatments, so waiting until standard options are used up can close doors. Bringing up trials at each decision point keeps the most options open.
What the Phases Mean
Trials are grouped into phases that reflect what question is being asked:
•Phase 1: Is it safe, and what is the right dose? These are usually small and open to people with several cancer types or with melanoma that has progressed on standard treatment. Some modern phase 1 trials of targeted or immune drugs do show meaningful responses.
•Phase 2: Does it work against melanoma specifically? These enroll larger groups with defined melanoma situations and measure response rate and how long benefit lasts.
•Phase 3: Is it better than the current standard? These randomly assign people to the new approach or to standard care (often with everyone receiving at least an active treatment), usually in hundreds to thousands of participants.
"Expanded access" (also called compassionate use) is a separate pathway that can sometimes provide an unapproved drug outside a trial when no trial is available — your oncologist can tell you whether it applies.
How Eligibility Works
Every trial has detailed inclusion and exclusion criteria. For advanced melanoma, the factors that most often decide eligibility are:
•Tumor mutations. Some trials require a BRAF V600 mutation; others require its absence, or a less common change such as NRAS or KIT. Testing from the staging workup matters here.
•Prior treatment. Many trials specify how many previous lines of therapy you can have had, and whether you have already received a checkpoint inhibitor.
•Brain metastases. Some trials exclude active brain metastases; others are designed specifically for them. Treated, stable brain disease is often allowed.
•Organ function and overall health, measured with blood tests and a performance-status score, and autoimmune history, which can affect eligibility for immune-based trials.
•Measurable disease — at least one tumor that can be tracked on scans — and, for cell-therapy trials, a lesion that can be surgically removed to manufacture the product.
Not meeting the criteria for one trial says nothing about another. A trial coordinator can screen you quickly against several at once.
Where to Search
•ClinicalTrials.gov — the comprehensive registry of trials worldwide. Search "melanoma" plus your situation; the listings can be technical, so use them alongside one of the guided tools below.
•National Cancer Institute (NCI) — a curated, plain-language trial search, plus a contact center (1-800-4-CANCER) whose staff will help match you to trials.
•Melanoma Research Alliance and AIM at Melanoma — melanoma-specific trial finders that ask a series of questions and return trials you may fit, with contact details.
•Academic melanoma centers — comprehensive cancer centers and university melanoma programs keep their own lists and can screen you for both their trials and multicenter ones.
Bring the results to your oncologist. They can tell you which trials are realistic given your history and help arrange a referral or a screening visit.
•What is being tested, and what is the comparison? Is there randomization? If so, what does each group receive — does everyone get at least standard treatment?
•What is the goal for me — shrinking the melanoma, keeping it stable, lowering recurrence risk — and how will that be measured?
•What are the known and possible risks, and how do they compare with standard treatment?
•What extra visits, scans, biopsies, and travel are required, and over how long? What costs are covered by the trial, and what falls to me or my insurance?
•What happens if the treatment does not work or I need to stop? Can I still get standard therapy afterward, and can I leave the trial at any time?
You will be asked to sign an informed-consent document. It should answer these questions in writing; take it home, read it, and ask the study team about anything that is unclear. Enrolling is voluntary, and you can withdraw at any point without affecting your regular care.
What to Ask Your Doctor
Is a clinical trial a reasonable option for me right now, or at a specific point ahead?
Are there trials at this center I might qualify for, and are there multicenter trials worth traveling for?
Given my mutation status and prior treatment, what kinds of trials am I eligible for?
If I join a trial, would I keep seeing you, and how would my care be coordinated?
Could a referral to a larger melanoma center open up trial options I do not have here?
Conclusion
Clinical trials are woven through modern melanoma care, not tacked on at the end. They test new treatments before surgery, after surgery, and at every line of therapy for metastatic disease, and they are how the current standards became standard. A trial may or may not be right for you at a given moment, but it is always worth asking about — early, and again at each decision point.
Use ClinicalTrials.gov and the melanoma-specific finders to see what exists, then work through the list with an oncologist who can judge fit and arrange referrals. The consent process exists to make sure you understand exactly what you are agreeing to before you decide.
Sources
Clinical Guidelines & Peer-Reviewed Literature
Amaral T, Ottaviano M, Arance A, et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(1):10-30. PubMed
Swetter SM, Johnson D, Albertini MR, et al. Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2026;24(6):272-277. PubMed
Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813-823. PubMed
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Still Have Questions?
Chat with our AI guide for information about advanced melanoma